Fabrice Andre

Summary

Affiliation: Institut Gustave Roussy
Country: France

Publications

  1. doi request reprint Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
    Fabrice Andre
    Department of Medical Oncology, INSERM Unit U981, Paris Sud University, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:3693-702. 2013
  2. doi request reprint Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:28-33. 2013
  3. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
  4. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
  5. pmc Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
  6. ncbi request reprint Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection
    Nathalie Chaput
    Unite d immunologie, ERM0208 Institut National de la Sante et de la Recherche Medicale, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    J Immunol 172:2137-46. 2004
  7. doi request reprint Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy France, Villejuif, France
    Lancet Oncol 10:381-90. 2009
  8. doi request reprint 19q13-ERCC1 gene copy number increase in non--small-cell lung cancer
    Elsa Vanhecke
    INSERM U981, Villejuif, F 94805, France
    Clin Lung Cancer 14:549-57. 2013
  9. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
  10. ncbi request reprint Quantification of residual risk of relapse in breast cancer patients optimally treated
    Maria Vittoria Dieci
    INSERM Unit U981 and Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France
    Breast 22:S92-5. 2013

Detail Information

Publications65

  1. doi request reprint Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer
    Fabrice Andre
    Department of Medical Oncology, INSERM Unit U981, Paris Sud University, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:3693-702. 2013
    ..We evaluated whether dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, presented antitumor activity in FGFR-amplified breast cancers...
  2. doi request reprint Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 19:28-33. 2013
    ..In addition, they provide evidence for the development of immunotherapies in breast cancer patients...
  3. pmc Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial
    Jocelyne Jacquemier
    Department of Molecular Oncology, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, 232, bd Ste Marguerite, Marseille, 13009, France
    Breast Cancer Res 13:R109. 2011
    ..We searched for prognostic and predictive markers for docetaxel's benefit...
  4. pmc Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets
    Charles Swanton
    Cancer Research UK London Research Institute, 44 Lincoln s Inn Fields, London, WC2A 3PX, UK
    Genome Med 2:53. 2010
    ....
  5. pmc Prediction of the outcome of preoperative chemotherapy in breast cancer using DNA probes that provide information on both complete and incomplete responses
    Rene Natowicz
    AP HP, Hopital Tenon, Department of Gynecology, 4 rue de la Chine, F 75020 Paris, France
    BMC Bioinformatics 9:149. 2008
    ..Multigenic predictors were designed by selecting probe sets highly ranked in their predictions and tested using several validation sets...
  6. ncbi request reprint Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection
    Nathalie Chaput
    Unite d immunologie, ERM0208 Institut National de la Sante et de la Recherche Medicale, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    J Immunol 172:2137-46. 2004
    ..CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines...
  7. doi request reprint Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy France, Villejuif, France
    Lancet Oncol 10:381-90. 2009
    ..We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis...
  8. doi request reprint 19q13-ERCC1 gene copy number increase in non--small-cell lung cancer
    Elsa Vanhecke
    INSERM U981, Villejuif, F 94805, France
    Clin Lung Cancer 14:549-57. 2013
    ..The effect of ERCC1 gene copy number (CN) variation (CNV) on ERCC1 expression and the clinical outcome of patients with NSCLC are not known...
  9. ncbi request reprint HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer
    Fabrice Andre
    Breast Cancer Unit, Institut Gustave Roussy, Villejuif, France
    Breast Cancer Res Treat 108:183-90. 2008
    ..We examined the correlation between HER2 expression and pathologic complete response (pCR) to paclitaxel/FAC (T/FAC) preoperative chemotherapy in breast cancer...
  10. ncbi request reprint Quantification of residual risk of relapse in breast cancer patients optimally treated
    Maria Vittoria Dieci
    INSERM Unit U981 and Breast Cancer Unit, Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France
    Breast 22:S92-5. 2013
    ..Moreover, to exploit at the best the potential of each of these parameters, they should be integrated into algorithms to guide treatment decisions and to select those patients who may deserve the inclusion in clinical trials. ..
  11. ncbi request reprint The potential of exosomes in immunotherapy of cancer
    Nathalie Chaput
    ERIT M 02 08 INSERM, Unite d immunologie, Departement de Biologie Clinique, 12, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Blood Cells Mol Dis 35:111-5. 2005
    ..The first Phase I trial using DEX to immunize melanoma patients revealed the feasibility of DEX production in stage IV melanoma, their safety in long-term follow up and their bioactivity in vivo...
  12. ncbi request reprint The potential of exosomes in immunotherapy
    Nathalie Chaput
    Department of Clinical Biology, Institut Gustave Roussy, ERIT M 02 08 INSERM, 39 rue Camille Desmoulins, 94805 Villejuif, France
    Expert Opin Biol Ther 5:737-47. 2005
    ....
  13. ncbi request reprint Exosome-based immunotherapy
    Nathalie Chaput
    ERIT M 02 08 INSERM, Department of Clinical Biology, Institut Gustave Roussy IGR, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Cancer Immunol Immunother 53:234-9. 2004
    ..This review will present the main biological features pertaining to tumor or DC-derived exosomes, will emphasize their immunostimulatory function, and will discuss their implementation in cancer immunotherapy...
  14. doi request reprint Outcome in breast molecular subtypes according to nodal status and surgical procedures
    Chafika Mazouni
    Department of Breast Surgery, Institut Gustave Roussy, Villejuif, France
    Am J Surg 205:662-7. 2013
    ..The purpose of our study was to evaluate the surgical treatment and outcome of breast cancer according to molecular subtypes...
  15. doi request reprint The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
    Monica Arnedos
    Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France
    J Pathol 232:274-82. 2014
    ....
  16. ncbi request reprint [Adjuvant chemotherapy in non-small cell lung cancer]
    Laurent Taillade
    Comité de pathologie thoracique, Institut Gustave Roussy, Villejuif, France
    Bull Cancer 91:63-7. 2004
    ..In this article, the current status of adjuvant chemotherapy is reviewed, and future prospects are discussed...
  17. ncbi request reprint Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells
    Fabrice Andre
    Unite d immunologie, ERM0208 Institut National de la Sante et de la Recherche Medicale, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    J Immunol 172:2126-36. 2004
    ..These data imply that exosomes might be a transfer mechanism of functional MHC class I/peptide complexes to DC for efficient CTL activation in vivo...
  18. ncbi request reprint Chk1 as a new therapeutic target in triple-negative breast cancer
    Laurence Albiges
    Department of Medical Oncology, Villejuif F 94800, France
    Breast 23:250-8. 2014
    ..Here, we identified Checkpoint kinase 1 (Chk1) as a potent therapeutic target in triple-negative breast cancer (TNBC)...
  19. doi request reprint PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs
    Ken A Olaussen
    INSERM U981, Institut Gustave Roussy, DHU Torino, Villejuif, France
    Lung Cancer 80:216-22. 2013
    ..We further suggest DNA repair biomarkers should be analyzed in a larger context of multiple DNA repair pathway regulation...
  20. doi request reprint CXCR4 expression in early breast cancer and risk of distant recurrence
    Fabrice Andre
    Breast Medical Oncology Unit, Department of Radiation Therapy, Department of Pathology and Translational Research Unit UPRES EA03535, Institut Gustave Roussy, University of Paris XI, Villejuif, France
    Oncologist 14:1182-8. 2009
    ..e., liver, lung, brain, and bone)...
  21. ncbi request reprint Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Université Paris Sud, Le Kremlin Bicetre, France Electronic address
    Lancet Oncol 15:267-74. 2014
    ..Breast cancer is characterised by genomic alterations. We did a multicentre molecular screening study to identify abnormalities in individual patients with the aim of providing targeted therapy matched to individuals' genomic alterations...
  22. ncbi request reprint Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer
    Fabrice Andre
    Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, Villejuif, France
    J Clin Oncol 23:2996-3000. 2005
    ..We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines...
  23. doi request reprint Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array
    Fabrice Andre
    Translational Research Unit, UPRES03535, Paris Sud University, Orsay, France
    Clin Cancer Res 15:441-51. 2009
    ..We used high-resolution oligonucleotide comparative genomic hybridization (CGH) arrays and matching gene expression array data to identify dysregulated genes and to classify breast cancers according to gene copy number anomalies...
  24. doi request reprint A nomogram to predict for malignant diagnosis of BI-RADS Category 4 breast lesions
    Chafika Mazouni
    Department of Breast Oncology, Institut Gustave Roussy, Villejuif, France
    J Surg Oncol 102:220-4. 2010
    ..The purpose of this study was to develop and validate a nomogram for the prediction of individual probability of BC in patients with BI-RADS Category 4 lesions...
  25. doi request reprint Integration of host-related signatures with cancer cell-derived predictors for the optimal management of anticancer chemotherapy
    Laurence Zitvogel
    INSERM, U1015, Institut Gustave Roussy, Villejuif, France
    Cancer Res 70:9538-43. 2010
    ....
  26. doi request reprint Fine-needle aspiration for nucleic acid-ased molecular analyses in breast cancer
    Catherine Uzan
    Research Translational Laboratory, Histocytopathology Unit, Gustave Roussy Institute, 39 rue Camille Desmoulins, Villejuif, France
    Cancer 117:32-9. 2009
    ..The objective of the current study was to evaluate the quality and potential use of material obtained from fine-needle aspiration cytology (FNAC)...
  27. doi request reprint Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues
    Charles Ferte
    SITEP Phase 1 Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Eur J Cancer 47:2249-55. 2011
    ..Oral ulcers is a well-recognised adverse event (AE) of mTOR inhibitors. Paradoxically, little is known about its natural history, risk factors, and basic management...
  28. doi request reprint Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
    Fabrice Andre
    Breast Cancer Unit, Department of Medical Oncology, University Paris XI and Institut Gustave Roussy, Villejuif, France
    J Clin Oncol 28:5110-5. 2010
    ....
  29. pmc The anticancer immune response: indispensable for therapeutic success?
    Laurence Zitvogel
    INSERM, U805, Villejuif, France
    J Clin Invest 118:1991-2001. 2008
    ....
  30. doi request reprint The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy
    Monica Arnedos
    Department of Medical Oncology, Institut de Cancerologie Gustave Roussy, 94805 Villejuif, France
    Mol Oncol 6:204-10. 2012
    ..Mid and long term aims are to facilitate and speed up the process of drug development as well as to implement the concept of personalized medicine...
  31. pmc ERCC1 isoform expression and DNA repair in non-small-cell lung cancer
    Luc Friboulet
    INSERM Unité 981, and Département Hospitalo Universitaire Thorax Innovation, Institut Gustave Roussy, Villejuif, France
    N Engl J Med 368:1101-10. 2013
    ..Although several ongoing trials are evaluating the level of expression of ERCC1, no consensus has been reached regarding a method for evaluation...
  32. doi request reprint Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands
    Rosa Conforti
    Institut Gustave Roussy, U848, 94805 Villejuif, France
    Cancer Res 70:490-500. 2010
    ..Optimizing the anticancer effects of TLR3 agonists may require manipulating these chemokines or their receptors...
  33. ncbi request reprint New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer
    Cecile Vicier
    aInstitut National de la Santé et de la Recherche Médicale INSERM U981 bDepartment of Medical Oncology, Gustave Roussy Institute IGR, Villejuif, France
    Curr Opin Oncol 25:587-93. 2013
    ..Despite much interest, knowledge of the mechanism and molecular response to mTOR inhibitors is incomplete...
  34. ncbi request reprint Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers
    Samar Alsafadi
    INSERM U981 Identification of molecular predictors and new targets for cancer treatment, Gustave Roussy Cancer Institute, Villejuif, France
    Clin Breast Cancer 13:401-8. 2013
    ..We therefore investigated whether RARA gene amplification could be associated with sensitivity to retinoic acid derivatives in breast cancers...
  35. ncbi request reprint Chemoprevention of lung cancer
    Stephane Vignot
    Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805, Villejuif, France
    Recent Results Cancer Res 166:145-65. 2005
    ..New chemoprevention trials are planned with collaborative efforts of researchers involved in fundamental or clinical studies...
  36. doi request reprint Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing
    Jeannine de la Cruz
    Department of Medicine, Institut Gustave Roussy, 94805 Villejuif, France
    Hum Pathol 43:1932-9. 2012
    ....
  37. doi request reprint Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
    Luc Friboulet
    INSERM, U981 Institut de cancérologie Gustave Roussy IGR, Villejuif, France
    Clin Cancer Res 17:5562-72. 2011
    ..However, little is known about the molecular characteristics of ERCC1-positive and ERCC1-negative tumors...
  38. doi request reprint Implications of personalized medicine--perspective from a cancer center
    Thomas Tursz
    Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, 39 rue Camilles Desmoulins, Villejuif 94805, France
    Nat Rev Clin Oncol 8:177-83. 2011
    ..These considerations highlight the need for developing a consortium of comprehensive cancer centers to run clinical trials in rare, molecularly-defined populations, and implement high-throughput technologies for daily practice...
  39. doi request reprint Decision-making from multidisciplinary team meetings to the bedside: factors influencing the recruitment of breast cancer patients into clinical trials
    Chafika Mazouni
    Breast Cancer Group, Institut Gustave Roussy, Villejuif, France Electronic address
    Breast 23:170-4. 2014
    ....
  40. ncbi request reprint Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
    Fabrice Andre
    Department of Medical Oncology, INSERM Unit U981, Universite Paris Sud, Institut Gustave Roussy, Villejuif, France
    Lancet Oncol 15:580-91. 2014
    ..We aimed to assess whether the addition of the mTOR inhibitor everolimus to trastuzumab might restore sensitivity to trastuzumab...
  41. ncbi request reprint Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer
    Kathy D Miller
    Kathy D Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN Reshma L Mahtani, Sylvester Comprehensive Cancer Center, Miami, FL Kathy S Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL Liang Fang, Glenn Michelson, Genentech, South San Francisco, CA Howard A Burris, Sarah Cannon Research Institute, Nashville, TN Véronique Diéras, Institut Curie, Paris Fabrice Andre, Institut Gustave Roussy, Villejuif, France Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne Nadia Harbeck, Breast Cancer University of Munich, Germany Luca Gianni, San Raffaele Hospital, Milan Diana Crivellari, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy Sanne L de Haas, F Hoffmann La Roche, Basel, Switzerland
    J Clin Oncol 32:1437-44. 2014
    ..Our phase IIa study characterized the safety and efficacy of two human epidermal growth factor receptor 2 (HER2) -targeted agents, trastuzumab emtansine (T-DM1) and pertuzumab, in patients with HER2-positive metastatic breast cancer (MBC)...
  42. doi request reprint Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives
    Maria Vittoria Dieci
    Breast Cancer Unit, INSERM Unit U981, Gustave Roussy Institute, Villejuif, France
    Cancer Discov 3:264-79. 2013
    ..Efforts are being pursued to develop selective approaches for use against this pathway by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clinical trials to address these different issues...
  43. doi request reprint Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer
    Stephane Vignot
    Institut National de la Santé et de la Recherche Médicale INSERM U981, Villejuif, France
    J Clin Oncol 31:2167-72. 2013
    ..We undertook this study to compare genomic alterations identified in archived primary tumors from patients with NSCLC with those identified in metachronous or synchronous metastases...
  44. ncbi request reprint Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast
    Julien Grenier
    Department of Medical Oncology, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif
    Anticancer Res 27:547-55. 2007
    ..Pure or metaplastic squamous cell carcinoma (SCC) of the breast is a rare entity with an unclear pathogeny and aggressive clinical behaviour. An attempt was made to characterize its differential immunohistochemical and biological profile...
  45. ncbi request reprint Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors
    Francois Ghiringhelli
    Institut National de la Sante et de la Recherche Medicale, U805, Villejuif, France
    Nat Med 15:1170-8. 2009
    ..These results indicate that the NLRP3 inflammasome links the innate and adaptive immune responses against dying tumor cells...
  46. pmc Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology
    Charles Ferte
    Sage Bionetworks, Seattle, WA 98109, USA
    Clin Cancer Res 19:4315-25. 2013
    ..It provides a roadmap for the translation of such classifiers to clinical practice and makes key recommendations for good practice...
  47. doi request reprint Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation
    Mario Campone
    Department of Medical Oncology, Centre Rene Gauducheau, Boulevard Jacques Monod, Nantes Saint Herblain, France
    Crit Rev Oncol Hematol 78:195-205. 2011
    ....
  48. doi request reprint Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging
    Elisabeth Chereau
    Department of Surgery, Breast Cancer Group, Institut Gustave Roussy, Villejuif, France
    Clin Breast Cancer 10:113-8. 2010
    ..We evaluated the characteristics, treatments, and prognostic features of breast cancers diagnosed among BRCA1/2 mutation carriers either inside or outside screening programs that included MRI...
  49. ncbi request reprint Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    Fabrice Andre
    Breast Cancer Unit and Translational Research Unit, UPRES03535, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:2061-7. 2007
    ..A molecular marker may be prognostic of outcome or predictive of response to therapy, or a combination of both...
  50. ncbi request reprint Issues in clinical research for metastatic breast cancer
    Semih Dogan
    aINSERM Unit U981, Universite Paris Sud, Gustave Roussy bDepartment of Medical Oncology, Gustave Roussy, Villejuif, France
    Curr Opin Oncol 25:625-9. 2013
    ..These changes are impacting the conduct and design of clinical trials. This review describes the changing landscape of clinical research in metastatic breast cancer (MBC)...
  51. ncbi request reprint From the antigen-presenting cell to the antigen-presenting vesicle: the exosomes
    Noël Emile Célestin Schartz
    ERIT M 02 08 INSERM, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France
    Curr Opin Mol Ther 4:372-81. 2002
    ..The hypotheses accounting for exosome biogenesis will be outlined. Finally, we will describe their bioactivities and discuss their potential relevance and clinical implementation for cancer immunotherapy...
  52. doi request reprint Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer
    Emma Pailler
    Institut de Cancerologie Gustave Roussy, Villejuif, France
    J Clin Oncol 31:2273-81. 2013
    ..We evaluated whether ALK rearrangement diagnosis could be performed by using circulating tumor cells (CTCs)...
  53. ncbi request reprint Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors
    Roman Rouzier
    Department of Surgery, Institut Gustave Roussy, Villejuif, France
    Cancer 101:918-25. 2004
    ..The aim of the current study was to determine the predicting factors and the survival impact of breast conservation in patients with large breast tumors treated with neoadjuvant chemotherapy...
  54. doi request reprint Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups
    Fabrice Andre
    Department of Medical Oncology, Institut National de la Sante et de la Recherche Medicale, France
    Clin Cancer Res 18:1555-60. 2012
    ..The programs are being run by cooperative groups...
  55. doi request reprint Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients
    Fabrice Andre
    Department of Medical Oncology, Institut Gustave Roussy, France
    Curr Opin Oncol 22:547-51. 2010
    ..This review will summarize recent advances concerning the implication of tumor microenvironment in the response to chemotherapy...
  56. doi request reprint Molecular circuits of solid tumors: prognostic and predictive tools for bedside use
    Charles Ferte
    INSERM U981, Department of Medicine, Institut Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif, France
    Nat Rev Clin Oncol 7:367-80. 2010
    ..The advent of high-throughput strategies will also probably substitute monobiomarker strategies...
  57. ncbi request reprint The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?
    Fabrice Andre
    From the Department of Medical Oncology and INSERM Unit U981, Gustave Roussy Cancer Campus, Villejuif, France Department of Medical Oncology, Centre Paoli Calmettes, Marseille, France
    Am Soc Clin Oncol Educ Book 34:e5-e10. 2014
    ..Challenges and perspective in the field of precision medicine will include the prediction of resistance, the integration of immunology, and DNA repair in the genomic algorithms and the transfer of concepts to early-stage breast cancers. ..
  58. doi request reprint Personalized medicine in oncology: where have we come from and where are we going?
    Fabrice Andre
    Institut Gustave Roussy, Villejuif, France
    Pharmacogenomics 14:931-9. 2013
    ..Proposed solutions point out the use of liquid biopsies and systems biology approaches, for an easier implementation of personalized medicine at the bedside...
  59. ncbi request reprint Breast cancer with synchronous metastases: trends in survival during a 14-year period
    Fabrice Andre
    Breast Cancer Unit, Comite 050, Institut Gustave Roussy, 39 Rue C Desmoulins, 94805 Villejuif, France
    J Clin Oncol 22:3302-8. 2004
    ..This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis...
  60. ncbi request reprint The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy
    Lionel Apetoh
    Institut Gustave Roussy IGR, Villejuif, France
    Immunol Rev 220:47-59. 2007
    ..This knowledge may be clinically exploited to predict the immunogenicity and hence the efficacy of chemotherapeutic regimens...
  61. pmc Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha
    Sophie Viaud
    Institut National de la Sante et de la Recherche Medicale, Unité 805, Villejuif, France
    PLoS ONE 4:e4942. 2009
    ..Altogether, these data provide a mechanistic explanation on how Dex may stimulate non MHC restricted-anti-tumor effectors and induce tumor regression in vivo...
  62. pmc Triple-negative breast cancer: are we making headway at least?
    Monica Arnedos
    Breast Unit, Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Ther Adv Med Oncol 4:195-210. 2012
    ....
  63. doi request reprint Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis
    Intissar Akalay
    Unité INSERM U753, Institut de Cancerologie Gustave Roussy, Villejuif, France
    Cancer Res 73:2418-27. 2013
    ..Furthermore, they reveal EMT and autophagy as conceptual realms for immunotherapeutic strategies to block immune escape...
  64. ncbi request reprint [Supervision after breast cancer treatment]
    Shanna Rajpar
    Institut Gustave Roussy, unité de recherche UPRES EA 3535, service de pharmacologie et nouveaux traitements des cancers, 94805 Villejuif Cedex, France
    Rev Prat 63:1415-8. 2013
    ..The socio-economic consequences for these patients need to be evaluated and cardiovascular toxicities of chemotherapy and hormonal therapy are probably underestimated...
  65. ncbi request reprint Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer
    Fabrice Andre
    Institut Gustave Roussy, Villejuif, France
    Curr Med Res Opin 30:1007-16. 2014
    ..This study evaluated actual physician-reported treatments for advanced BC in Europe...